Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
UOX
MCID: URT049
MIFTS: 24

Urate Oxidase, Pseudogene (UOX)

Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Urate Oxidase, Pseudogene

About this section

MalaCards integrated aliases for Urate Oxidase, Pseudogene:

Name: Urate Oxidase, Pseudogene 57 13
Uricase 57
Uox 57

External Ids:

OMIM® 57 191540
Sources

Summaries for Urate Oxidase, Pseudogene

About this section
OMIM® : 57 In most mammals, the activity of urate oxidase (EC 1.7.3.3) catalyzes the oxidation of uric acid to allantoin; humans and some primates lack this enzyme activity. The loss of urate oxidase in the human during primate evolution predisposes man to hyperuricemia, a metabolic disturbance that can lead to gouty arthritis and renal stones (summary by Wu et al., 1994). (191540) (Updated 05-Mar-2021)

MalaCards based summary : Urate Oxidase, Pseudogene, also known as uricase, is related to gout and diabetes insipidus, nephrogenic, autosomal. An important gene associated with Urate Oxidase, Pseudogene is UOX (Urate Oxidase (Pseudogene)). The drugs Allopurinol and Rasburicase have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and endothelial.

Sources

Related Diseases for Urate Oxidase, Pseudogene

About this section

Diseases related to Urate Oxidase, Pseudogene via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 19)
# Related Disease Score Top Affiliating Genes
1 gout 10.7
2 diabetes insipidus, nephrogenic, autosomal 10.0
3 lymphoma, hodgkin, classic 10.0
4 lymphoma, non-hodgkin, familial 10.0
5 nephrolithiasis 10.0
6 diabetes insipidus 10.0
7 hypouricemia, renal, 1 9.9
8 hyperuricemia 9.9
9 burkitt lymphoma 9.9
10 nephrolithiasis, calcium oxalate 9.9
11 lesch-nyhan syndrome 9.9
12 obstructive nephropathy 9.9
13 urolithiasis 9.9
14 glucose intolerance 9.9
15 uremia 9.9
16 severe combined immunodeficiency 9.9
17 chronic kidney disease 9.9
18 fatty liver disease 9.9
19 47,xyy 9.9

Graphical network of the top 20 diseases related to Urate Oxidase, Pseudogene:



Diseases related to Urate Oxidase, Pseudogene
Sources

Symptoms & Phenotypes for Urate Oxidase, Pseudogene

About this section

Clinical features from OMIM®:

191540 (Updated 05-Mar-2021)

Sources

Drugs & Therapeutics for Urate Oxidase, Pseudogene

About this section

Drugs for Urate Oxidase, Pseudogene (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 8)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Allopurinol Approved Phase 2 315-30-0 2094
2
Rasburicase Approved, Investigational Phase 1 134774-45-1
3
Uric acid Investigational Phase 1 69-93-2 1175
4 Antirheumatic Agents Phase 1
5
Febuxostat Approved 144060-53-7 134018
6 Protective Agents
7 Antioxidants
8 Pharmaceutical Solutions

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout Completed NCT01356498 Phase 3
2 Randomized, Multicenter, Double-blind, Placebo-controlled Efficacy and Safety Study of 8 mg PEG-uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout Completed NCT00325195 Phase 3
3 A Randomized Double-Blind, Placebo-Controlled Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy Recruiting NCT04596540 Phase 3 SEL-212A;SEL-212B
4 A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy Completed NCT03905512 Phase 2 SEL-212;SEL-037;SEL-110;KRYSTEXXA®
5 A Phase II Multidose Study of Intravenous PEG-uricase in Patients With Refractory Gout Completed NCT00111657 Phase 2
6 A Cohort Dose-Escalation Phase 1 Study of Intravenous Infusion of Uricase-PEG 20 Unknown status NCT01021241 Phase 1
7 A Cohort Dose-Escalation Phase 1 Study of Intramuscular Injection of Uricase-PEG 20 Unknown status NCT01038947 Phase 1
8 An Open Label, Single-dose, Dose-increasing Study to Assess the Safety, Tolerability, PK and Preliminary PD of PEGylated Recombinant Candida Urate Oxidase (SSS11) for Injection in Chinese Healthy Adult Volunteers Not yet recruiting NCT04047394 Phase 1 PEGylated recombinant candida urate oxidase
9 Association of Maternal Uric Acid With Maternal Condition and Fetal Outcome in Pregnant Women With Hypertension Unknown status NCT01523327
10 Differential Effects of Uric Acid and Xanthine Oxidoreductase on Endothelial Function and Oxydative Stress Completed NCT03395977 Placebos;Febuxostat;Rasburicase

Search NIH Clinical Center for Urate Oxidase, Pseudogene

Sources

Genetic Tests for Urate Oxidase, Pseudogene

About this section
Sources

Anatomical Context for Urate Oxidase, Pseudogene

About this section

MalaCards organs/tissues related to Urate Oxidase, Pseudogene:

40
Liver, Kidney, Endothelial, Brain, Heart, Retina, Small Intestine
Sources

Publications for Urate Oxidase, Pseudogene

About this section

Articles related to Urate Oxidase, Pseudogene:

(show top 50) (show all 1085)
# Title Authors PMID Year
1
Evolutionary history and metabolic insights of ancient mammalian uricases. 57 61
24550457 2014
2
Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. 57 61
8290593 1994
3
Structural analysis of the gene encoding rat uricase. 61 57
1783398 1991
4
Urate oxidase: primary structure and evolutionary implications. 61 57
2594778 1989
5
A human genomic sequence highly homologous to the 3'-untranslated region of rat uricase mRNA. 57 61
3178807 1988
6
Localization of the human urate oxidase gene (UOX) to 1p22. 57
1395718 1992
7
Human urate oxidase gene: cloning and partial sequence analysis reveal a stop codon within the fifth exon. 57
2403354 1990
8
Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase. 57
3344434 1988
9
A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. 57
3029599 1987
10
HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. 57
3821905 1987
11
Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? 57
13937884 1962
12
A 3D electrochemical biosensor based on Super-Aligned Carbon NanoTube array for point-of-care uric acid monitoring. 61
33601134 2021
13
Sensing soluble uric acid by Naip1-Nlrp3 platform. 61
33547278 2021
14
The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. 61
33601190 2021
15
Association between plasma uric acid and insulin resistance in type 2 diabetes: A Mendelian randomization analysis. 61
33227361 2021
16
Natural Products and Extracts as Xantine Oxidase Inhibitors - A Hope for Gout Disease? 61
32723252 2021
17
A new uricase from Bacillus cereus SKIII: Characterization, gene identification and genetic improvement. 61
33122065 2020
18
Targeting Uric Acid Prevents Brain Injury and Anxiety in a Rat Model of Hemorrhagic Shock. 61
33394973 2020
19
Impact of uric acid on liver injury and intestinal permeability following resuscitated hemorrhagic shock in rats. 61
33231951 2020
20
Associations of serum iron and ferritin with hyperuricemia and serum uric acid. 61
32458239 2020
21
The Role of Soluble Uric Acid in Modulating Autophagy Flux and Inflammasome Activation during Bacterial Infection in Macrophages. 61
33322651 2020
22
New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. 61
32893671 2020
23
Determination of PEGylation homogeneity of polyethylene glycol-modified canine uricase. 61
33247595 2020
24
An electrochemical biosensor based on multi-wall carbon nanotube-modified screen-printed electrode immobilized by uricase for the detection of salivary uric acid. 61
32794003 2020
25
Electrochemical synthesis and characterization of poly(thionine)-deep eutectic solvent/carbon nanotube-modified electrodes and application to electrochemical sensing. 61
33057990 2020
26
Silk Fibroin-Based Materials for Catalyst Immobilization. 61
33114465 2020
27
New insight into the molecular mechanism of the trehalose effect on urate oxidase stability. 61
33000700 2020
28
Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study. 61
32720081 2020
29
Ion-exchange medium coated with abundant small zwitterions for the purification of soluble proteins. 61
32967535 2020
30
New Middle Miocene Ape (Primates: Hylobatidae) from Ramnagar, India fills major gaps in the hominoid fossil record. 61
32900315 2020
31
Pharmacokinetics of Polyethylene Glycol-Modified Canine Uricase Following Single and Multiple Intravenous Injections in Cynomolgus Monkeys. 61
32162270 2020
32
Species and sex differences in the blood clearance and immunogenicity of PEGylated uricase: A comparative 26-week toxicity study in rats and monkeys. 61
31610209 2020
33
J-shaped relationship between serum uric acid levels and the risk of ischemic stroke in high-risk individuals: A hospital-based observational study. 61
32447150 2020
34
Biomimetic polysaccharide-cloaked lipidic nanovesicles/microassemblies for improving the enzymatic activity and prolonging the action time for hyperuricemia treatment. 61
32639489 2020
35
The role of uric acid in inflammasome-mediated kidney injury. 61
32452918 2020
36
Enzyme-coupled fluorescence sensor for sensitive determination of uric acid and uricase inhibitor. 61
32706938 2020
37
Hyperuricemia Predisposes to the Onset of Diabetes via Promoting Pancreatic β-Cell Death in Uricase-Deficient Male Mice. 61
32312870 2020
38
A highly sensitive uric acid electrochemical biosensor based on a nano-cube cuprous oxide/ferrocene/uricase modified glassy carbon electrode. 61
32606291 2020
39
[Resonance light scattering spectroscopy can directly characterize protein solubility]. 61
32895202 2020
40
Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia. 61
32518351 2020
41
Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. 61
32620200 2020
42
Therapeutic approaches in the treatment of gout. 61
32620199 2020
43
Synthesis of carbon quantum dots with iron and nitrogen from Passiflora edulis and their peroxidase-mimicking activity for colorimetric determination of uric acid. 61
32594256 2020
44
Multimodal Enzyme Delivery and Therapy Enabled by Cell Membrane-Coated Metal-Organic Framework Nanoparticles. 61
32352801 2020
45
High-Dose IV Administration of Rasburicase Suppresses Anti-rasburicase Antibodies, Depletes Rasburicase-Specific Lymphocytes, and Upregulates Treg Cells. 61
32462555 2020
46
High Performance Molecular Detection Biosensor Using Plasmonic Spiral Nanoantenna Based on Optical Fiber. 61
32919490 2020
47
De novo design of functional zwitterionic biomimetic material for immunomodulation. 61
32523997 2020
48
Construction and expression of recombinant uricase‑expressing genetically engineered bacteria and its application in rat model of hyperuricemia. 61
32323736 2020
49
Perfecting a high hypoxanthine phosphoribosyltransferase activity-uricase KO mice to test the effects of purine- and non-purine-type xanthine dehydrogenase (XDH) inhibitors. 61
31971609 2020
50
The consequences of altered microbiota in immune-related chronic kidney disease. 61
32437554 2020
Sources

Variations for Urate Oxidase, Pseudogene

About this section
Sources

Expression for Urate Oxidase, Pseudogene

About this section
Search GEO for disease gene expression data for Urate Oxidase, Pseudogene.
Sources

Pathways for Urate Oxidase, Pseudogene

About this section
Sources

GO Terms for Urate Oxidase, Pseudogene

About this section
Sources

Sources for Urate Oxidase, Pseudogene

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....